Japanese Chugai Revises First Quarter Profit Outlook
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Chugai Pharmaceutical said April 22 its net income in the first quarter dropped by roughly 50 percent compared to the same period last year due to weak sales of its influenza vaccine Tamiflu (oseltamivir). However, the Tokyo-based company revised and lifted its profit outlook until the end of the year in part due to lower than expected drug repricing efforts by the government